OBSIDIAN THERAPEUTICS
Obsidian Therapeutics is a developer of a next-generation cell and gene therapies created to extend adoptive immunotherapy to every patient with cancer.The company's next-generation cell and gene therapies with pharmacologic operating systems provide exquisite control of protein activity in cells and create adoptive cell therapies with new functions that are under control of the treating physician using simple, safe, orally-active, marketed drugs, enabling patients to improve on the current generation of cell therapies.
OBSIDIAN THERAPEUTICS
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2015-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.obsidiantx.com
Total Employee:
51+
Status:
Active
Contact:
(781) 806-6245
Total Funding:
164.5 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Font Awesome Global Site Tag Sitelinks Search Box Amazon
Similar Organizations
Ankyra
Ankyra is a biotech company developing anchored immunotherapy for cancer treatments.
Aratana Therapeutics
Aratana Therapeutics develops innovative therapies for the animal health industry.
b.well Connected Health
b.well Connected Health provides an integrated solution for consumer engagement, holistic health management, and cost containment.
CareRx
CareRx is a provider of pharmacy services to seniors communities.
Century Therapeutics
Century Therapeutics is a developer of allogeneic living drugs created to offer treatment for cancer.
Cybin
Cybin is a life sciences company dedicated in advancing psychedelic therapeutics with the goal of transforming mental healthcare.
Denteric
Denteric is developing a vaccine based on research conducted at the University of Melbourne.
Dracen Pharmaceuticals
Dracen Pharmaceuticals is a developer of novel glutamine antagonists created to deliver improved outcomes for cancer patients.
Dyne Therapeutics
Dyne Therapeutics is a developer of targeted therapies intended for serious muscle diseases.
EIP Pharma
EIP Pharma Provides Healthcare Services.
Everest Medicines
Everest Medicines is dedicated to its mission of developing and commercializing novel transformative pharmaceutical therapies for patients.
Genomic Prediction
Genomic Prediction provides advanced genetic testing for IVF.
Icosavax
Icosavax is focused on developing safe and effective vaccines against infectious diseases that address important unmet medical needs.
Jaguar Health
Jaguar Health brings naturally derived important health solutions to all animals of the world, as proprietary.
Kalderos
Kalderos provides a SaaS based drug discount management solution, which identifies, checks, and resolves non-compliance.
Neukio Biotherapeutics
Neukio Biotherapeutics is a developer of allogenic immune cell therapies for treatment of cancer.
Nivien Therapeutics
Nivien Therapeutics is developing the first small molecule drugs to enhance both chemo and immunotherapies.
Pyxis Oncology
Pyxis Oncology is a developer of antibody therapeutics intended to promote the body's immune response to cancer.
Sante Basque Developpement
Sante Basque Developpement is owns and operates mental health hospitals.
Syndesi Therapeutics
Syndesi Therapeutics develops a drug candidate for the treatment of consecutive cognitive disorders of various neurological conditions.
Tiburio Therapeutics
Tiburio Therapeutics is a developer of drug compounds intended to treat tumors and endocrine diseases.
Tune Therapeutics
Tune Therapeutics is an epigenetic programming platform for the treatment of disease.
Vico Therapeutics
Vico Therapeutics is a developer of ribonucleic acid (RNA) modulating therapies.
Westlake Therapeutics
The company is committed to the development of a variety of innovative cell therapy products for rare diseases, cancer, etc.
Zucara Therapeutics
Zucara Therapeutics is developing the first once-daily therapeutic to prevent hypoglycemia (low blood sugar) in patients with diabetes.
Current Advisors List
Board_member
Current Employees Featured
Michael Gilman Founder & CEO @ Obsidian Therapeutics
Founder & CEO
Steve Shamah Senior Vice President & Head of Research @ Obsidian Therapeutics
Senior Vice President & Head of Research
2016-09-01
Jan Ter Meulen CSO @ Obsidian Therapeutics
CSO
Paul Wotton CEO @ Obsidian Therapeutics
CEO
Parnian Zia-Amirhosseini VP and Head of Regulatory Affairs & Quality Assurance @ Obsidian Therapeutics
VP and Head of Regulatory Affairs & Quality Assurance
Catherine Stehman-Breen CDO @ Obsidian Therapeutics
CDO
Karen Brown SVP of Intellectual Property and Legal Affairs @ Obsidian Therapeutics
SVP of Intellectual Property and Legal Affairs
Kirsten Kester Senior Vice President, Business Development @ Obsidian Therapeutics
Senior Vice President, Business Development
2022-01-01
Ryan Daws Chief Financial Officer @ Obsidian Therapeutics
Chief Financial Officer
2019-01-01
Shyam Subramanian SVP of Technical Operations and COE @ Obsidian Therapeutics
SVP of Technical Operations and COE
Founder
Investors List
The Column Group
The Column Group investment in Series B - Obsidian Therapeutics
Vertex Ventures HC
Vertex Ventures HC investment in Series B - Obsidian Therapeutics
RA Capital Management
RA Capital Management investment in Series B - Obsidian Therapeutics
Amgen Ventures
Amgen Ventures investment in Series B - Obsidian Therapeutics
Bristol Myers Squibb
Bristol Myers Squibb investment in Series B - Obsidian Therapeutics
Logos Capital
Logos Capital investment in Series B - Obsidian Therapeutics
Atlas Venture
Atlas Venture investment in Series B - Obsidian Therapeutics
Deep Track Capital
Deep Track Capital investment in Series B - Obsidian Therapeutics
Samsara BioCapital
Samsara BioCapital investment in Series B - Obsidian Therapeutics
Surveyor Capital
Surveyor Capital investment in Series B - Obsidian Therapeutics
Official Site Inspections
http://www.obsidiantx.com Semrush global rank: 3.54 M Semrush visits lastest month: 4.15 K
- Host name: 2.198.243.35.bc.googleusercontent.com
- IP address: 35.243.198.2
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
More informations about "Obsidian Therapeutics"
Obsidian Therapeutics - Crunchbase Company Profile …
Obsidian Therapeutics is a developer of a next-generation cell and gene therapies created to extend adoptive immunotherapy.See details»
Pioneering engineered cell and gene therapies | Obsidian …
Obsidian is a volcanic glass that is used to make sharp and precise blades. Reflecting our namesake, our approach enables precise, patient-specific engineering of cell and gene …See details»
Obsidian Therapeutics - 2025 Company Profile - Tracxn
Mar 26, 2025 Obsidian Therapeutics - Developer of engineered cell and gene therapies for multiple diseases. Raised a total funding of $325M over 3 rounds from 28 investors.See details»
Obsidian Therapeutics 2025 Company Profile: …
Information on valuation, funding, cap tables, investors, and executives for Obsidian Therapeutics. Use the PitchBook Platform to explore the full profile.See details»
Obsidian Therapeutics: Revenue, Worth, Valuation & Competitors …
About Obsidian Therapeutics Obsidian Therapeutics is a Biotech related company founded in 2015 and based in Cambridge with an estimated revenue of $19.2M, and 124 employees. It …See details»
Obsidian Therapeutics, Inc. Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Obsidian Therapeutics, Inc. of Bedford, MA. Get the latest business insights from Dun & Bradstreet.See details»
Obsidian Therapeutics Company Overview, Contact Details
Apr 3, 2024 Learn more about Obsidian Therapeutics's company details, contact information, competitors, and more. Find accurate contact data easily with LeadIQ. Book a demo today.See details»
Obsidian Therapeutics (USA) Funding: $325M - Medical Startups
Mar 24, 2025 USA | Funding: $325M (+) Website: https://obsidiantx.com/ Obsidian Therapeutics is a developer of a next-generation cell and gene therapies created to extend adoptive ...See details»
Obsidian Therapeutics, Inc. (Obsidian Therapeutics, Inc.) - 药物管 …
Obsidian is headquartered in Cambridge, MA. The Company has collaborations with Bristol Myers Squibb and Vertex Pharmaceuticals. For more information, please visit www.obsidiantx.com …See details»
Obsidian Therapeutics Announces Leadership …
“Mike and the team have built a world-class organization, executed on a strategic transformative partnership, and established Obsidian’s technology as the premier synthetic biology platform for regulating gene and cell-based therapeutics.See details»
Obsidian Therapeutics Company Profile: Overview and Full News …
Obsidian Therapeutics, based in Massachusetts, is a pioneering company in the field of engineered therapeutics, focusing on precision cell and gene therapy. They utilize their …See details»
Obsidian Therapeutics – Funding, Valuation, Investors, News
Obsidian Therapeutics is pioneering controllable cell and gene therapies to deliver transformative outcomes for patients with intractable diseases. Obsidian’s programs apply our cytoDriveTM …See details»
Working at Obsidian Therapeutics | Glassdoor
See what employees say it's like to work at Obsidian Therapeutics. Salaries, reviews, and more - all posted by employees working at Obsidian Therapeutics.See details»
Obsidian Therapeutics, Inc. Company Profile | Cambridge, MA ...
Find company research, competitor information, contact details & financial data for Obsidian Therapeutics, Inc. of Cambridge, MA. Get the latest business insights from Dun & Bradstreet.See details»
Obsidian Therapeutics Announces Appointment of William Pao, …
CAMBRIDGE, Mass., June 4, 2024 – Obsidian Therapeutics, Inc., a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced the appointment of …See details»
MD Anderson and Obsidian Therapeutics announce FDA clearance …
FDA granted IND clearance for OBX-115, Obsidian’s lead engineered TIL therapy, for the treatment of patients with solid tumorsSee details»
Obsidian Therapeutics Announces Closing of $115 Million Series B ...
Funding to Advance Pipeline of Engineered TIL Therapies for Solid Tumors into Clinical Studies CAMBRIDGE, Mass., September 9, 2021 – Obsidian Therapeutics, Inc., a biotechnology …See details»
OpenText Announces Availability of Titanium X Enabling new …
1 day ago OpenText™ today introduced the availability of Project Titanium X, now ready with Cloud Editions 25.2 (CE 25.2), the culmination of two years of strategic engineering powering …See details»
Obsidian Therapeutics to Present Preclinical Data Supporting OBX …
Obsidian will present preclinical data supporting a more patient-centric tumor tissue procurement procedure using core needle biopsy for OBX-115 manufacturing in patients with NSCLC, …See details»
OBX-115 | Investigational IL2-free TIL therapy with mbIL15 for …
The Phase I FIH clinical trial for OBX-115 is currently recruiting patients with metastatic melanoma. Obsidian’s investigational lead program, OBX-115, is a novel, IL2-free, tumor …See details»